AVIR Atea Pharmaceuticals Inc
Price (delayed)
$3.065
Market cap
$262.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
$199.08M
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding
Highlights
Atea Pharmaceuticals's quick ratio has increased by 37% YoY and by 27% QoQ
The debt has declined by 32% year-on-year and by 11% since the previous quarter
Atea Pharmaceuticals's net income has decreased by 24% YoY but it has increased by 3.2% from the previous quarter
Atea Pharmaceuticals's EPS has decreased by 23% YoY but it has increased by 3.4% QoQ
The company's equity fell by 21% YoY and by 4.3% QoQ
Key stats
What are the main financial stats of AVIR
Market
Valuations
Earnings
Shares outstanding
85.53M
Market cap
$262.13M
Enterprise value
$199.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$192.95M
Net income
-$168.39M
EBIT
-$167.46M
EBITDA
-$167.04M
Free cash flow
-$135.5M
Per share
Balance sheet
Liquidity
EPS
-$2
EPS diluted
-$2
Free cash flow per share
-$1.61
Book value per share
$5.2
Revenue per share
$0
TBVPS
$5.51
Total assets
$464.67M
Total liabilities
$25.8M
Debt
$1.64M
Equity
$438.87M
Working capital
$443.75M
Debt to equity
0
Current ratio
24.85
Quick ratio
24.44
Net debt/EBITDA
0.38
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.4%
Return on equity
-35.9%
Return on invested capital
-49.7%
Return on capital employed
-37.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVIR stock price
How has the Atea Pharmaceuticals stock price performed over time
Intraday
-1.13%
1 week
2.17%
1 month
-1.45%
1 year
-23.18%
YTD
-8.51%
QTD
-8.51%
Financial performance
How have Atea Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$192.95M
Net income
-$168.39M
Gross margin
N/A
Net margin
N/A
Atea Pharmaceuticals's net income has decreased by 24% YoY but it has increased by 3.2% from the previous quarter
The operating income is down by 18% YoY but it is up by 3.8% QoQ
Growth
What is Atea Pharmaceuticals's growth rate over time
Valuation
What is Atea Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atea Pharmaceuticals's EPS has decreased by 23% YoY but it has increased by 3.4% QoQ
AVIR's P/B is 68% lower than its 5-year quarterly average of 1.9
The company's equity fell by 21% YoY and by 4.3% QoQ
Efficiency
How efficient is Atea Pharmaceuticals business performance
AVIR's return on invested capital has dropped by 58% year-on-year
The company's return on equity has shrunk by 55% YoY and by 2.9% QoQ
The ROA has shrunk by 52% YoY and by 3.1% QoQ
Dividends
What is AVIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVIR.
Financial health
How did Atea Pharmaceuticals financials performed over time
Atea Pharmaceuticals's quick ratio has increased by 37% YoY and by 27% QoQ
The current ratio rose by 36% year-on-year and by 29% since the previous quarter
The debt is 100% smaller than the equity
The debt has declined by 32% year-on-year and by 11% since the previous quarter
The company's equity fell by 21% YoY and by 4.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.